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Background: Chronic kidney disease (CKD) is a known risk factor for cardiovascular events and all-cause mortality.
We investigate the relationship between CKD stage, proteinuria, hypertension and these adverse outcomes in the
people with diabetes. We also study the outcomes of people who did not have monitoring of renal function.
Methods: A cohort of people with type 1 and 2 diabetes (N = 35,502) from the Quality Improvement in Chronic
Kidney Disease (QICKD) cluster randomised trial was followed up over 2.5 years. A composite of all-cause mortality, car-
diovascular events, and end stage renal failure comprised the outcome measure. A multilevel logistic regression model
was used to determine correlates with this outcome. Known cardiovascular and renal risk factors were adjusted for.
Results: Proteinuria and reduced estimated glomerular filtration rate (eGFR) were independently associated with
adverse outcomes in people with diabetes. People with an eGFR <60 ml/min, proteinuria, and hypertension have the
greatest odds ratio (OR) of adverse outcome; 1.58 (95% CI 1.36-1.83). Renal function was not monitored in 4460 (12.6%)
people. Unmonitored renal function was associated with adverse events; OR 1.35 (95% CI 1.13-1.63) in people with
hypertension and OR 1.32 (95% CI 1.07-1.64) in those without.
Conclusions: Proteinuria, eGFR < 60 ml/min, and failure to monitor renal function are associated with cardiovascular
and renal events and mortality in people with diabetes.
Keywords: Unmonitored, Primary care, Cardiovascular risk, Proteinuria, Estimated glomerular filtration rateBackground
Diabetes mellitus is an increasingly common condition
and is associated with increased risk of cardiovascular
events and mortality [1,2]. Furthermore, diabetes is the
most common cause of end-stage renal disease (ESRD);
in the United States it account for up to 45% of all new
cases of ESRD [3]. Chronic kidney disease (CKD) is a
risk factor for cardiovascular disease and mortality both
in the general population [4,5] and amongst people with
diabetes [6]. The two components of CKD; reduced esti-
mated glomerular filtration rate (eGFR) and proteinuria* Correspondence: andy@mcgov.co.uk
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reproduction in any medium, provided the orhave been shown to be independently associated with
cardiovascular events and mortality in the general popu-
lation and in high risk populations [7-9].
The National Institute for Health and Clinical Excel-
lence (NICE) currently recommends all people with dia-
betes in England and Wales regularly have their renal
function tested, including testing for albuminuria [10].
However, people with CKD complicating diabetes are
not always identified and are sometimes sub-optimally
managed in primary care [11]. Early identification of
CKD and intervention with renoprotective measures,
particularly the use of angiotensin converting enzyme in-
hibitors (ACEIs) and angiotensin receptor blockers
(ARBs), has been shown to be effective in slowing pro-
gression of renal disease and in reducing cardiovasculartral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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also reduces the risk of progression [17].
We investigated the association of eGFR and protein-
uria on adverse vascular and renal outcomes in people
with diabetes, with or without hypertension, in a com-
munity setting. In addition we investigated the associ-
ation of these outcomes in people who did not have
monitoring of their renal function.
Methods
We performed a cohort analysis on all adults with diabetes
in the Quality Improvement in Chronic Kidney Disease
(QICKD) trial database. The QICKD trial was a three-
armed cluster randomised controlled trial to analyse the
impact of quality improvement interventions on blood
pressure in people with renal disease [18]. Randomisation
occurred at the primary care practice level. Practices were
allocated to usual practice (no intervention), provision of
clinical guidelines and prompts, or audit-based education.
A reduction was of 2.41 mmHg (CI 0.59-4.29 mmHg; p =
0.012) was demonstrated with audit based education. How-
ever, neither intervention was found to have any impact on
cardiovascular outcomes during the follow-up period. The
trial database comprises routinely collected general practice
(GP) data from 127 primary care practices across England;
a nationally representative sample of urban, sub-urban
and rural practices in London, Surrey, Sussex, Leicester,Figure 1 Hierarchy of clinical tests used for the diagnosis of proteinu
and Lamb et al. [31].Birmingham and Cambridge between January 2006 and
December 2010 [19]. There were additional records, of
varying durations, for each person prior to these dates.
Data recorded between January 2006 and June 2008 were
used to determine the baseline characteristics of the
people included in the study. A second data collection
was undertaken at 30 months to obtain follow-up data.
We included all adults with type 1 and 2 diabetes. These
patients were identified using a validated method for iden-
tifying correctly coded cases of diabetes from UK primary
care records [20]. This method included analysis of dia-
betes read codes (e.g. read codes C10E and C10F are used
for type 1 and type 2 diabetes respectively in UK primary
care) in combination with documented investigation re-
sults. A person was defined as having diabetes if they had
read codes for either type 1 or type 2 diabetes or labora-
tory values consistent with the World Health Organisa-
tion (WHO) diagnostic criteria for diabetes [21,22] prior
to, or during the baseline period; a fasting blood glucose >
7.1 mmol/l, non-fasting blood glucose > 11.1 mmol/l, or
HbA1c > 59 mmol/mol (7.5%). People with a recorded
diagnosis of gestational diabetes, or elevated blood glucose
results during pregnancy were excluded unless they subse-
quently developed diabetes outside of pregnancy.
England has a registration based primary health care sys-
tem. With very few exceptions the whole population is reg-
istered with a single GP. Patients access non-emergencyria. Threshold values are adapted from the 2008 NICE guidelines [10]
eGFR <= 60 ml/min
              (N=21,985)
Proteinuria (N=20,574)
Hypertension (N=78,344)
Figure 2 Area proportional Venn diagram demonstrating the
interrelationship between hypertension, reduced eGFR, and
proteinuria in people with diabetes.
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all hospital attendances including emergencies. Patients all
have a unique ID called NHS number, which is attached to
all their medical records. The health system has been pro-
gressively computerised since the 1990s [23]. Since 2004
there have been pay-for-performance indicators for chronic
disease management, to which CKD was added in 2006
[23]. Remuneration for these is based on extracts from rou-
tine computer data [24]. Routinely collected primary care
data in the UK, therefore, provides a highly comprehensive
patient record.
Outcomes
A composite outcome measure of incident stroke, transi-
ent ischaemic attacks (TIA), myocardial infarction (MI),
death, advanced coronary artery disease, heart failure, and
progression to end stage renal failure during the follow up
period was used. Advanced coronary artery disease com-
prised revascularisation procedures (percutaneous coron-
ary angioplasty and coronary bypass surgery) and patients
with preinfarction syndrome. Preinfarction syndrome con-
sists of newly recorded diagnosis of unstable angina, an-
gina at rest, refractory angina, progressive angina, and
acute coronary syndrome not otherwise recorded as a
myocardial infarction.
Predictors
Established predictors of adverse vascular and renal events
were controlled for. These comprise: age, sex, ethnicity,
deprivation status, smoking status, alcohol intake, body
mass index (BMI); comorbid heart failure, hypertension,
ischemic heart disease (IHD), advanced coronary artery
disease, renal failure requiring dialysis, and dyslipidaemia;
a previous history of stroke, transient ischemic attack
(TIA), myocardial infarction (MI), coronary artery revas-
cularisation procedures; and current use of aspirin, lipid
lowering medication, ACEI or ARB medication, and other
anti-hypertensive medications.
Demographic factors were extracted from GP records.
Deprivation scores were derived from national statistics
using patient postcodes at the point of data extraction
(in compliance with data governance standards) [25].
Deprivation scores provide a combined measure of
household income, education, healthcare provision, and
living environment for the UK at small spatial scales
[25]. Each locality is ranked by decile from most de-
prived to least deprived.
Smoking status and alcohol intake were based on the
most recently recorded value for each factor before the
start of the follow up period. Hypertension was defined as
a recorded diagnosis of hypertension, or repeated blood
pressure measurements greater than 130/80 mmHg
[26-28]. A previous history of stroke, TIA, MI, or coron-
ary artery revascularisation procedure and comorbiddiagnoses of coronary heart failure, IHD, and dialysis were
recorded as either present or absent based on the pres-
ence of a recorded diagnostic codes. Dyslipidaemia was
subdivided into total cholesterol (TC), high density lipo-
protein (HDL) cholesterol, and low density lipoprotein
(LDL) cholesterol for analysis. Prescription records were
used to define medication use. The additional risk factors
analysed were: CKD stage, proteinuria (see below), urine
albumin creatinine ratio (ACR), and most recent glycated
haemoglobin (HbA1C) result.
The severity of CKD was stratified by stage, using the
NICE definition [10], based on two eGFR measurements
where available and the presence or absence of protein-
uria. People with an eGFR of 60–90 ml/min or eGFR >
90 ml/min with proteinuria were classified as having
CKD stages 1–2. People with an eGFR of < 60 ml/min
were classified as having CKD stages 3–5. People who
were on dialysis were also included in this category re-
gardless of their creatinine measurements. eGFR values
were calculated from serum creatinine using the 4-
variable Modified Diet in Renal Disease (MDRD) equa-
tion [29,30]. This remains the standard equation used in
UK primary care since the implementation of a national
quality standard in 2006 for calculating eGFR across all
laboratories in the UK.
Proteinuria was analysed using the diagnostic criteria
described by NICE [30]: The presence of proteinuria was
determined by examining a hierarchy of clinical tests,
with albumin creatinine ratio (ACR) being the highest
(Figure 1). Where ACR testing had been done it
was distinctly categorised by severity; normal (<2.5 mg/
mmol males, <3.5 mg/mmol females), microalbumi-
nuria (2.5–30 mg/mmol males, 3.5–30 mg/mmol fe-
males) and macroalbuminuria (>30 mg/mmol) [31].
Figure 3 Adverse outcomes during 30 month follow up of 35,502 people with diabetes.
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tion if they did not have an eGFR recording and urine
protein test during the 30 month baseline period.Statistical analysis
The data were first refined, to adjust for inputting errors,
by removing numeric values above or below the max-
imum physiological limits. A complete case analysis was
performed to account for the effects of loss to follow-up.
A multilevel binary logistic regression model was built
to account for variation between primary care practices.
Patients were nested within GP practice using a random
intercept. This was performed using the statistical pack-
age R and the multilevel R package lme4 [32]. Model se-
lection was performed using the approach described by
Maindonald and Braun [33]; minimising the Bayesian in-
formation criterion using backward stepwise elimination.
Time to event models (Cox proportional hazard models)
were also produced using the statistical package R.
Model validation was performed for all models.
A Kaplan-Meier survival analysis was conducted to
identify event free survival differences by CKD stage in
people with and without hypertension. A logrank test
was performed.Ethical considerations
No patient identifiable data was used in the analysis de-
scribed here. The original QICKD study was approved
by the Oxford Research Ethics Committee (Committee
C). The ethical considerations of the QICKD study are
described elsewhere [19,34].Results
A total of 741,913 people were included for analysis, of
whom 35.914 (4.8%) had diabetes. We excluded people
who died or left the practice before the start of the fol-
low up period (n = 123), or if they were aged less than
18 at the start of the follow up period (n = 142,533).
From this remaining adult cohort 35,502 people met the
diagnostic criteria for diabetes.
The mean age of this cohort was 63.6 years (standard
deviation of 14.3 years). Males made up 54% of the popu-
lation. Diabetes was coded as type 1 diabetes in 1,202
(3.4%) people and type 2 in 30,767 (86.7%). The remaining
3,533 (9.9%) had other codes consistent with a diagnosis
of diabetes or investigations consistent with the diagnostic
criteria but where diabetes type was not specified.
Overall 15,813 (44.5%) people were identified with CKD.
Hypertension was found to be present in almost everyone
with diabetes and CKD; 15,244 (96.4%) (Figure 2). 5,862
people were found to have hypertension without CKD.
A total of 3,144 people (8.9%) in the cohort had an ad-
verse outcome during the 30 month follow up period
(Figure 3). All-cause mortality was the most common
adverse outcome with 1,495 cases (4.2%), equating to an
annual mortality of 17 per 1,000 person years. Non-fatal
cardiovascular events occurred in a total of 1,531 people
(4.3%). 1,691 (4.8%) people were lost to follow up before
suffering an adverse event. These people were included
in our final analysis. The demographics of the popula-
tion are provided in Table 1.
A diagnosis of heart failure, stroke, TIA, ischaemic heart
disease, or MI before the start of follow up were all found
to be independent predictors of adverse outcome (Table 2).
Table 1 Clinical characteristics of the 35,502 people with diabetes included for analysis
Characteristic n (%) Characteristic n (%)
Age: mean (±SD) 63.6 years (±14.3) Investigations
Gender: female 16,322 (45.97) ACR: not monitored 13,104 (36.91)
Gender: male 19,180 (54.03) ACR: normal 16,960 (56.00)
Ethnicity ACR: microalbuminuria 4,623 (13.02)
White 15,222 (42.9) ACR: macroalbuminuria 815 (2.30)
Mixed 406 (1.1) HbA1c: not measured 3,435 (9.7)
Asian 6,215 (17.5) HbA1c: < 7.5% 19,648 (55.3)
Black 2,183 (6.1) HbA1c: > 7.5% 12,419 (35.0)
Other 2,187 (6.1) Total cholesterol: not monitored 2,046 (5.8)
Not recorded 9,289 (26.2) Total cholesterol: < 5.0 mmol/l 31,553 (88.9)
Smoking Status Total cholesterol: > 5.0 mmol/l 1,903 (5.4)
Not recorded 7,474 (21.05) LDL cholesterol: not monitored 15,678 (44.16)
Never smoked 16,349 (46.10) LDL cholesterol: normal 14,612 (41.16)
Current Smoker 6,620 (18.65) LDL cholesterol: high 5,212 (14.68)
Ex-smoker 5,059 (14.25) HDL cholesterol: not monitored 5,850 (16.48)
Alcohol Consumption HDL cholesterol: normal 24,372 (68.65)
Not recorded 12,272 (34.57) HDL cholesterol: low 5,280 (14.87)
No alcohol 11,250 (31.70) No Hypertension
Light alcohol 10,124 (28.52) Renal function not monitored 2,200 (6.20)
Excess alcohol 1,725 (4.86) No CKD 15,229 (42.90)
Previous excess alcohol 131 (0.37) CKD all stages
Comorbidities Hypertension 569 (1.60)
Heart failure 1,550 (4.37) Renal function not monitored 2,260 (6.37)
Dialysis 97 (0.27) No CKD 5,862 (16.51)
Stroke 1,438 (4.05) CKD stages 1–2 7,581 (21.35)
Transient ischaemic attack 1,060 (2.99) CKD stages 3–5 3,987 (11.23)
Ischaemic heart disease 6,328 (17.82) CKD stages 3–5 with proteinuria 3,676 (10.35)
Coronary artery operation 2,322 (6.54) LDL cholesterol: not monitored 15,678 (44.16)
Myocardial infarction 1,895 (5.34)
Abbreviation: SD, Standard deviation.
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nicity, BMI, HbA1c, total cholesterol, and the use of as-
pirin. These variables were therefore removed from the
multilevel logistic regression model.
The odd ratios for adverse outcomes increased with
declining renal function, proteinuria, and hypertension
(Table 3). Cox regression analysis also demonstrates in-
creasing hazard ratios with declining renal function
(Table 4). Event free survival analysis for people with
CKD with and without hypertension showed their sum-
mative effect on adverse outcomes (Figure 4).
A total of 4,460 (12.6%) people had incomplete CKD
screening during the 2.5 year baseline period. This com-
prised 1,574 (4.4%) people with no serum creatinine re-
corded and 3,478 (9.8%) untested for proteinuria. People
with unmonitored renal function, both with and withouthypertension, were found to have significantly higher inci-
dence of adverse vascular and renal outcomes than those
with normal renal function. People with unmonitored renal
function were found to have lower prescription rates of
ACE inhibitors and ARBs (41.4%, 95% CI 40.2-42.6%) than
people with no evidence of CKD (54.8%, 95% CI 54.1-
55.4%) and people with CKD (71.1%, 95% CI 70.3-71.9%).
They were also younger, more likely to drink excessive al-
cohol and smoke, had lower prescription rates of other
medications, were more likely to have other missing data,
and had worse mean cholesterol values (Table 5).
Discussion
Principal findings
We report three principal findings: Both reduced eGFR,
and proteinuria are independent predictors of adverse
Table 2 Univariate and multivariate odds ratios of an adverse outcome over 30 months of follow up, adjusted for CKD
and hypertension
Univariate analysis Multivariate analysis (MLM)
Characteristic: Odds ratio (95% CI) P = Odds ratio (95% CI) P =
Age (years) 1.06 (1.06-1.06) <0.001 1.05 (1.05-1.05) <0.001
Gender: female 1.00 (reference) - 1.00 (reference) -
Gender: male 1.21 (1.13-1.31) <0.001 1.24 (1.14-1.36) <0.001
Ethnicity
White 1.00 (reference) - - -
Mixed 0.61 (0.41-0.92) 0.019 - -
Asian 1.00 (0.99-1.01) 0.488 - -
Black 0.98 (0.97-1.00) 0.016 - -
Other 0.95 (0.80-1.13) 0.591 - -
Missing 1.02 (0.94-1.11) 0.640 - -
Smoking Status
Not recorded 1.18 (1.07-1.31) 0.002 0.95 (0.84-1.08) 0.472
Never smoked 1.00 (reference) - 1.00 (reference) -
Current Smoker 1.39 (1.24-1.57) <0.001 1.38 (1.24-1.54) <0.001
Ex-smoker 1.82 (1.61-2.06) <0.001 1.18 (1.05-1.32) 0.005
Alcohol Consumption
Not recorded 0.93 (0.85-1.01) 0.090 1.07 (0.96-1.20) 0.223
No alcohol 1.00 (reference) - 1.00 (reference) -
Light alcohol 0.87 (0.79-0.96) 0.004 0.88 (0.79-0.97) 0.013
Excess alcohol 1.04 (0.87-1.23) 0.688 1.24 (1.03-1.49) 0.024
Previous excess alcohol 1.16 (0.66-2.02) 0.610 1.04 (0.56-1.93) 0.895
Comorbidities
BMI (kg/m2) 1.01 (0.99-1.02) 0.276 - -
Heart failure 3.39 (2.99-3.83) <0.001 1.30 (1.13-1.49) <0.001
Dialysis 3.03 (1.88-4.89) <0.001 1.76 (1.04-2.99) 0.036
Stroke 3.96 (3.49-4.48) <0.001 2.26 (1.98-2.59) <0.001
Transient ischaemic attack 3.27 (2.82-3.79) <0.001 1.58 (1.34-1.86) <0.001
Ischaemic heart disease 3.03 (2.80-3.27) <0.001 1.64 (1.47-1.84) <0.001
Coronary artery operation 2.63 (2.35-2.94) <0.001 1.26 (1.09-1.44) 0.001
Myocardial infarction 2.88 (2.56-3.24) <0.001 1.23 (1.06-1.42) 0.005
Investigations
ACR: not monitored 0.77 (0.71-0.84) <0.001 1.33 (1.19-1.50) <0.001
ACR: normal 1.00 (reference) - 1.00 (reference) -
ACR: microalbuminuria 1.46 (1.31-1.62) <0.001 1.16 (1.01-1.32) 0.034
ACR: macroalbuminuria 2.70 (2.26-3.23) <0.001 2.32 (1.88-2.86) <0.001
HbA1c: not measured 0.99 (0.98-1.01) 0.226 - -
HbA1c: < 7.5% 1.00 (reference) - - -
HbA1c: > 7.5% 1.16 (1.01-1.33) 0.224 - -
Total cholesterol: not monitored 0.89 (0.76-1.05) 0.160 - -
Total cholesterol: < 5.0 mmol/l 1.00 (reference) - - -
Total cholesterol: > 5.0 mmol/l 0.88 (0.74-1.04) 0.134 - -
LDL cholesterol: not monitored 1.13 (1.05-1.22) 0.002 1.23 (1.08-1.40) 0.002
LDL cholesterol: normal 1.00 (reference) - 1.00 (reference) -
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Table 2 Univariate and multivariate odds ratios of an adverse outcome over 30 months of follow up, adjusted for CKD
and hypertension (Continued)
LDL cholesterol: high 0.85 (0.75-0.96) 0.007 1.15 (1.01-1.31) 0.030
HDL cholesterol: not monitored 1.09 (0.98-1.20) 0.106 1.19 (1.02-1.39) 0.025
HDL cholesterol: normal 1.00 (reference) - 1.00 (reference) -
HDL cholesterol: low 1.13 (1.02-1.25) 0.022 1.17 (1.05-1.31) 0.006
Multilevel model performance: Random effects:
Bayesian information criteria (BIC) 19022 Intercepts for GP practice:
Log-likelihood −9312 Variance 0.111
ROC curve statistic 0.767 Standard deviation 0.334
Abbreviations: MLM, multilevel model; CI, confidence interval.
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hypertension, using the diagnostic threshold recommended
by national guidelines. People with unmonitored renal
function do worse that those who are monitored and ap-
pear to receive suboptimal medical therapies.
The combination of proteinuria and reduced eGFR is
associated with the highest risk of adverse outcomes in
people with and without hypertension. In people with
hypertension and normal eGFR, proteinuria, also signifi-
cantly increases the odds of adverse outcomes.
Almost all patients with CKD had hypertension whether
their CKD was diagnosed by the presence of proteinuria or
reduced eGFR. There were, however, a considerable num-
ber of people with hypertension and no evidence of renal
impairment. However, CKD testing in people with diabetes
and hypertension is currently suboptimal: just over 10% of
people had not had appropriate monitoring for CKD by
measurement of eGFR and assessment for proteinuria.
People with unmonitored renal function have a higher
risk of adverse outcomes than those with normal renal
function. This group has the lowest prescription rates of
antihypertensive medication, lipid lowering drugs, and as-
pirin, suggesting people in this group receive suboptimalTable 3 Adjusted odd ratios for vascular and renal events and
30 months of follow up, by CKD and hypertension category
Univariate analy
Odds ratio (95% CI)
No Hypertension
Renal function not monitored 1.21 (1.00-1.47)
No CKD 1.00 (reference)
CKD all stages 3.86 (2.15-6.94)
Hypertension
Renal function not monitored 2.07 (1.76-2.43)
No CKD 1.16 (1.01-1.33)
CKD stages 1–2 1.66 (1.48-1.88)
CKD stages 3–5 2.39 (2.10-2.73)
CKD stages 3–5 with proteinuria 4.38 (3.88-4.94)
Abbreviation: CI, confidence interval.therapy. They also had higher rates of excess alcohol use
and smoking. Whether these differences reflect variation
in provision of healthcare or in attitudes to healthcare re-
mains uncertain.
Implications of the findings
This study highlights the importance of frequent moni-
toring of eGFR and proteinuria in people with diabetes.
In particular, careful monitoring of renal function and
testing for proteinuria is essential for people with hyper-
tension and diabetes due to the very high proportion of
people with renal impairment in this group.
It is plausible that failure to monitor renal function is
associated with wider neglect in clinical management al-
though whether this is due to patient factors or health-
care factors is unclear. Computerised prompts and other
recall systems should perhaps focus on those at highest
risk i.e. not monitored and not prescribed antihyperten-
sive medication.
Comparison with literature
The prevalence of CKD stages 3–5 in people with hyper-
tension and diabetes is reported to be 43%, [35] in closemortality of 35,502 people with diabetes, over
sis Multivariate analysis (MLM)
P = Odds ratio (95% CI) P =
0.053 1.32 (1.07-1.64) 0.011
1.00 (reference) -
<0.001 1.34 (0.93-1.92) 0.117
<0.001 1.35 (1.13-1.63) 0.001
0.038 0.97 (0.84-1.11) 0.629
<0.001 1.19 (1.03-1.36) 0.015
<0.001 1.13 (0.98-1.31) 0.090
<0.001 1.58 (1.36-1.83) <0.001
Table 4 Adjusted hazard ratios (Cox regression analysis)
for adverse outcomes in 35,502 people with diabetes,
over 30 months of follow up, by CKD and hypertension
category
Hazard ratio (95% CI) P =
No Hypertension
Renal function not monitored 1.49 (1.23-1.80) 0.011
No CKD 1.00 (reference) -
CKD all stages 1.62 (0.76-3.42) 0.060
Hypertension
Renal function not monitored 1.55 (1.32-1.82) <0.001
No CKD 0.98 (0.85-1.12) 0.765
CKD stages 1–2 1.31 (1.16-1.47) <0.001
CKD stages 3–5 1.14 (1.00-1.31) 0.050
CKD stages 3–5 with proteinuria 1.72 (1.52-1.95) <0.001
Abbreviation: CI, confidence interval.
log rank test < 0.001
log rank test < 0.001
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Figure 4 Kaplan-Meier event free survival curves by CKD category in
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studies report a similar association between CKD and
hypertension in people with diabetes [36]. However, we
find this proportion increases to 72.2% if people with
CKD stage 1 and 2 are included.
Previous studies in the UK report the prevalence of
eGFR screening to be 92–82% in people with diabetes
over a 2 year period [11,37] compared with 95.6% over
30 months in our study. The prevalence of ACR screen-
ing is reported as 55.2% over 2 years [37], again very
similar to our study (63.1%). The association between
absence of assessment for CKD and vascular and renal
outcomes has not previously been investigated; though
we have previously reported that people not on diabetes
disease registers appear to receive suboptimal care [38].
A similar additive association between the proteinuria
and eGFR components of renal disease has been re-
ported with vascular and renal events and mortality in
the general population and, high risk groups and in
people with diabetes [7-9,39-41]. However the combinedNo CKD
Unmonitored for CKD
CKD all stages
No CKD
Proteinuria + normal eGFR
Unmonitored for CKD
No proteinuria + reduced eGFR
Proteinuria + reduced eGFR
Normotensive
Hypertensive
Loss to follow up
people with normotension and hypertension.
Table 5 Characteristics of people without monitored
renal function compared to those with monitored
renal function
Renal function
not monitored
(N = 4460) n (%)
Renal function
monitored
(N = 31042) n (%)
P =
Age: mean (±SD) 59.1 years (±16.5) 64.2 years (±13.9) <0.001
Gender: male 2,434 (54.6%) 16,764 (53.9%) 0.432
Ethnicity N = 2,227 N = 23,986
White 1,232 (55.3) 13,990 (58.3)
Mixed 37 (1.7) 369 (1.5)
Asian 480 (21.6) 5,735 (23.9)
Black 210 (9.4) 1,973 (8.2)
Other 268 (12.0) 1,919 (8.0) <0.001
Smoking Status N = 2765 N = 25263
Never smoked 1,562 (56.5) 14,787 (58.5)
Current Smoker 741 (26.8) 5,879 (18.2)
Ex-smoker 462 (16.7) 4,597 (18.2) <0.001
Alcohol Consumption N = 1,662 N = 21568
No alcohol 736 (44.3) 10,514 (48.7)
Light alcohol 707 (42.5) 9,417 (43.7)
Excess alcohol 194 (11.7) 1,531 (7.1)
Previous excess alcohol 25 (1.5) 106 (0.5) <0.001
Investigations
HbA1c: not monitored 1,496 (33.5) 1,939 (6.2) <0.001
HbA1c: mean (±SD) 8.16% (±2.09) 8.55 (±2.07) <0.001
Total cholesterol: not
monitored
1,413 (31.7) 633 (2.0) <0.001
Total cholesterol: mean
(±SD)
4.93 mmol/l
(±1.15)
4.60 mmol/l
(±1.08)
<0.001
LDL cholesterol: not
monitored
2,510 (56.3) 13,168 (42.4) <0.001
LDL cholesterol: mean
(±SD)
2.70 mmol/l
(±0.99)
2.51 mmol/l
(±0.91)
<0.001
HDL cholesterol: not
monitored
1,688 (37.8) 4,162 (13.4) <0.001
HDL cholesterol: mean
(±SD)
1.35 mmol/l
(±0.39)
1.29 mmol/l
(±0.38)
<0.001
Medications
ACE/ARBs prescribed 1,847 (41.4) 20,403 (65.7) <0.001
Lipid lowering drugs
prescribed
2,134 (47.8) 24,136 (77.8) <0.001
Aspirin prescribed 801 (18.0) 9,081 (29.3) <0.001
For ethnicity, smoking status, and alcohol consumption only those with
recorded values are included. Abbreviations: SD, standard deviation.
McGovern et al. BMC Nephrology 2013, 14:198 Page 9 of 11
http://www.biomedcentral.com/1471-2369/14/198impact of these factors with hypertension has not previ-
ously been explored in diabetes.
Limitations of the method
The limitations of this study include those of using rou-
tine data [42]. In particular the potential for ascertainmentbias in data categories where a significant proportion of
data has not been collected (e.g. smoking status and al-
cohol consumption). For this reason we have included
the complete population for analysis with ‘not recorded’
categories incorporated to identify potential associa-
tions with unrecorded data and adverse outcomes.
Smoking status and alcohol consumption not recorded
were not significantly associated with worse outcomes;
OR 0.95 (95% CI 0.84-1.08) and OR 1.07 (95% CI 0.96-
1.20) respectively.
Urine samples are frequently tested by clinicians using
reagent strips, the results of which may not always be
coded, resulting in underreporting of proteinuria test-
ing. However, it is likely that there is a bias for coding
positive test results which would not explain the in-
creased risk of adverse outcomes in the apparently un-
monitored group.
The causative factors for increased adverse outcomes
in people with unmonitored renal function cannot be
fully determined. Therefore the benefit of improving
screening in this unmonitored group cannot be dir-
ectly established.
Even with a large cohort the short duration of follow-
up (2.5 years) is also a limitation here. A longer follow-
up period, ideally at least five years would be preferable.
Many things, including assessing health economic im-
pact would be possible to estimate given change over
5 years or more. The large sample size makes possible
lack of power to identify significant associations un-
likely in this study, although weak associations may still
be missed.
We have previously demonstrated that the population
demographics of the QICKD cohort provide a close age
and gender match to the diversity of the English popula-
tion (from census data) although ethnic minorities ap-
pear to be under represented [43]. These results should
not, however, be extrapolated to dissimilar populations
or different healthcare settings.
Further research
Further work is needed to demonstrate whether im-
proved screening of renal function in people with dia-
betes leads in a reduction in vascular and renal events
and mortality.
Conclusions
CKD and proteinuria are associated with worse health
outcomes in people with diabetes, and this effect is addi-
tive. People with diabetes, who are not monitored for
renal disease, have an increased risk of adverse events
and appear to receive suboptimal medical therapy.
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